SciELO - Scientific Electronic Library Online

vol.114 issue4Insulin level and insulin sensitivity indices among healthy children and adolescentsConcurrent validity and interobserver reliability of the EPInfant pediatric perceived exertion rating scale among healthy Chilean children author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Archivos argentinos de pediatría

Print version ISSN 0325-0075On-line version ISSN 1668-3501


FIGUEROA TURIENZO, Carlos M et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in a retrospective cohort of children and adolescents who received an allogeneic transplantation in Argentina. Arch. argent. pediatr. [online]. 2016, vol.114, n.4, pp.337-342. ISSN 0325-0075.

Introduction. Hematopoietic cell transplantationis a therapy with a risk of transplant-related mortality (TRM), which may vary depending on prior comorbidities. The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) is an instrument developed to measure this risk. There are very few reports on its use in pediatrics. The objective of this study was to validate the HCT-CI in a pediatric cohort of allogeneic hematopoietic-cell transplantation recipients in Argentina. Population and methods. Retrospective cohort made up of 140 transplant patients at Hospital J. P. Garrahan between 2008 and 2012. Medical records were reviewed to identify patient history and course. The HCT-CI was estimated for each patient, who was classified as having a low (score: 0), intermediate (score: 1-2) or high (score: >3) risk. Survival was estimated for each group using the Kaplan-Meier method and compared with the log-rank test. For malignancies, relapse was considered an event consistent with TRM. A p value <0.05 was considered significant. Results. The median score in the HCT-CI was 1 (r: 0-6). A score of 0 was observed in 45.7% of patients, 1-2 in 40.7%, and >3 in 13.6%. The most common comorbidities included obesity, infection, pulmonary and liver involvement. TRM was 14.1% among patients with a score of 0; 43.7% with a score of 1-2, and 52.6% with a score >3. Differences were observed among the survival curves of the three groups (p = 0.01). Conclusion. The HCT-CI demonstrated to be an effective tool to predict the risk of TRM in our setting.

Keywords : Comorbidity; Hematopoietic stem cell transplantation; Non-relapse mortality; Pediatrics.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License